Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the Evercore ISI 2nd Annual HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the Evercore ISI 2nd Annual HealthCONx Conference.
- Location: Boston, MA
- Presentation date: Wednesday December 4, 2019
- Presentation time: 8:00 a.m. ET
A live audio webcast and archive of the presentation will be available at http://ir.mirumpharma.com
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.
Contacts
Media Contact:
Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi@canalecomm.com
Investor Contact:
Ian Clements, Ph.D.
650-667-4085
ir@mirumpharma.com
